Compare F5 Inc (FFIV) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs GSK plc — how do they compare? F5 Inc trades at $479.83 (market cap $26.14B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 3.5× F5 Inc's market cap, and GSK plc pays a 3.9% dividend while F5 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and GSK plc for 93 Days on average.
| FFIV | GSK | |
|---|---|---|
Market Cap | $26.14B | $91.88B |
Volume | 503,146 | 7,730,529 |
Sector | Technology | Health |
52-Week High | $469.79 | $61.18 |
52-Week Low | $223.99 | $43.24 |
Typical Hold Time | 38 Days | 93 Days |
Enterprise Value | $24.78B | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $479.83, up 2.82% today and near its 52-week high, reflecting strong momentum. The stock shows bullish technical signals with recent earnings beats and robust revenue growth, reaching $3.09 billion in 2025. Positive sentiment is driven by leadership in AI security and strategic partnerships, though valuation multiples like a P/E of 36.78 suggest premium pricing. Cash flow remains healthy with $268 million net inflow in 2025, supporting operational strength.
Outlook is cautiously optimistic with growth in AI and security markets offering upside, but risks include high valuation and competitive pressures. Analysts are mixed with a $416.60 consensus target below current price, indicating potential overvaluation. Investors should weigh solid fundamentals against elevated multiples for balanced risk-reward.
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
